Geoffrey Porges
Stock Analyst at Leerink Partners
(1.49)
# 3,517
Out of 5,154 analysts
114
Total ratings
47.37%
Success rate
-1.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Maintains: Outperform | $36 → $49 | $22.21 | +120.62% | 9 | Mar 2, 2026 | |
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $26.61 | +110.45% | 10 | Dec 15, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $764.93 | +11.12% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $67.36 | -28.74% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $367.60 | -41.24% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $232.35 | -41.90% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $29.72 | -62.99% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $145.14 | -48.33% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $45.00 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $13.58 | -26.36% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $460.82 | -62.02% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $27.66 | +203.69% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $55.27 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $13.20 | +362.12% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $188.08 | - | 8 | Mar 16, 2017 |
Arcus Biosciences
Mar 2, 2026
Maintains: Outperform
Price Target: $36 → $49
Current: $22.21
Upside: +120.62%
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $26.61
Upside: +110.45%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $764.93
Upside: +11.12%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $67.36
Upside: -28.74%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $367.60
Upside: -41.24%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $232.35
Upside: -41.90%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $29.72
Upside: -62.99%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $145.14
Upside: -48.33%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $45.00
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $13.58
Upside: -26.36%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $460.82
Upside: -62.02%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $27.66
Upside: +203.69%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $55.27
Upside: -
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $13.20
Upside: +362.12%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $188.08
Upside: -